posing evidence for such a role has been reviewed by Jones (1982) .
More recently, additional supporting evidence that documents a high-affinity binding site for H3-tryptamine in rat brain homogenates has been presented Kellar and Cascio, 1982) . Since then, other investigators have also demonstrated that tryptamine binding sites are present in the CNS and are distinct from those of serotonin binding sites (Rommelspacher and Kaufmann, 1983; Wood et al., 1984) . Tryptamine binding has been found to be strongly inhibited by beta-carbolines (Cascio and Kellar, 1983; Rommelspacher and Kaufmann, 1983; Wood et al., 1984) , kynuramine (Charlton et al., 1984) , and derivatives of phenylethylamine (PEA) (Cascio and Kellar, 1983; Martin et al., 1984) . This suggests that several endogenously found compounds are possible ligands for the tryptamine binding site.
All the binding studies described above have been performed on brain homogenate preparations. Although these homogenate studies have provided data on tryptamine binding in large brain regions, they fail to delineate the localization of tryptaminebinding sites among brain nuclear groups. The in vitro autoradiographic technique developed by Young and Kuhar (1979) allows precise delineation of binding sites among brain nuclei. Two preliminary reports have described the use ofthis technique to elucidate the localization of tryptamine binding sites in the CNS (McCormack et al., 1983; Perry et al., 1982) . The purpose of the present investigation is to employ in vitro autoradiographic technique to map tryptamine binding sites in the rat and dog CNS.
Materials and Methods
Male Sprague-Dawley rats, weighing between 250 and 300 gm, were anesthetized with chloral hydrate and perfused transcardially with ice cold isotonic saline. Brains were immediately removed, slowly frozen to -2o"C, and used for binding studies within 24 hr. Dogs of either sex, weighing between 10 and 15 kg, were premeditated with atropine and acetylpromazine and anesthetized with pentobarbital. Dogs were cannulated in the carotid artery and perfused with ice cold isotonic saline over a 30 min period. The spinal cord and lower brain stem were removed and slowly frozen to -20°C after gross dissection into the following six regions: medulla, Cl to C5, C6 to T2, T3 to T13, Ll to L3, and L4 to S3.
To establish appropriate biochemical parameters for HI-tryptamine binding, rat brains were first sectioned at 20 pm on an American Optical cryostat at -20°C. Serial sections from the rostra1 commissure through the caudal hippocampus were thaw-mounted onto clean glass slides and refrozen until used. Slide-mounted sections were then placed in preincubation baths for 5 and 2 min each, transferred to an incubation bath for 60 min, and subsequently washed twice in trizma citrate buffer, as described in Table 1 . After the last bath, the sections were scraped off the slides using a 2.4-cm-diameter glass microfiber filter (Whatman) and placed in 10 ml of Scintiverse E scintillation fluid. After a minimum of 12 hr, the sections were counted in a liquid scintillation counter (Beckman Model LS7000). The amount of protein in 20 pm tissue Wash II 6 .25 min, 4°C sections was determined using the Coomassie Brilliant Blue method, as described by Macart and Gerbaut (1982) .
For autoradiography, both canine and rodent tissue sections were cut at 20 pm and processed according to the protocol described in Table 1 with the exception that tissues were incubated for only 30 min. This shorter incubation time was used because it provided a higher specific/ nonspecific binding ratio. Brains from rats were sectioned from the rostra1 pole of the forebrain to the caudal medulla. The canine caudal brain stem and spinal cord were also sectioned, incubated and processed for autoradiography. Autoradiography of tissue sections was carried out as described previously (Beitz et al., 1984) . After the last bath, sections were briefly dipped in distilled water, dried, and apposed to LKB Ultrotilm. After an appropriate exposure period, the film was developed in D-19 developer and analyzed using a computerized photometer system. Since tritium standards were not used in this analysis, the density values obtained represent relative values for the nuclear groups studied. In addition, no attempt was made to account for the regional whitematter quenching, which varies according to the different ratios of gray to white matter in the brain regions studied (Unnerstall and Kuhar, 1985) . Brain structures were identified according to the atlas of Paxinos and Watson (1982) for the rat and of Singer (1962) for the dog.
Tritiated tryptamine hydrochloride, with a specific activity ranging between 23.9 and 41.5 Ci/mmol, was purchased from New England Nuclear. Fluoxetine hydrochloride was a gift from Eli Lilly and Co. (Indianapolis, IN). Lysergic acid diethylamide (LSD) was a gift from The National Institute on Drug Abuse. All other chemicals, unless otherwise stated, were obtained from Sigma Chemical Co. (St. Louis, MO).
Results

Binding kinetics
The rate of association of tritiated tryptamine with its binding site was determined by varying the length of the incubation period, while maintaining the bath temperature at 25°C. H3-tryptamine bound rapidly with a half-time of association at 3.8 min and saturation in approximately 15 min (Fig. 1) . Analysis by linear regression of the same data provides the association rate constant (K,,) of 0.059 m-l min-I. In contrast, the rate of dissociation of tritiated tryptamine was determined by varying the total wash time while maintaining the wash bath temperature at 4°C. The half-time of dissociation under these con- ditions was determined to be 15.5 min while the dissociation rate constant (Km,) was calculated to be 0.045 min-l (Fig. 2) . If pargyline hydrochloride was omitted, specific H'-tryptamine binding was dramatically reduced because of the rapid oxidation by MAO.
Saturation studies Slide-mounted tissue sections were incubated with different concentrations of H%-yptamine to determine total binding, and also in the presence of excess unlabeled tryptamine (1 OOO-fold excess) to determine nonspecific binding. All sections were incubated for 60 min to establish equilibrium. This longer incubation bath time was needed primarily at the lower concentrations of tritiated tryptamine. Scatchard analysis of this data (Scatchard plot, Fig. 3B ) suggests an equilibrium dissociation constant (K,) of 4.79 f 1.55 nh4 (n = 3, ranging from 3.12 to 7.89 nM) and the maximum number of binding sites (B,,,) was 195 f 34 fmol/mg protein. Linear regression of the data yields a Hill coefficient (n,) of 0.97 + 0.04 (Fig. 3A) , suggesting binding to a single class of sites and lack of any apparent cooperativity. Previous studies by Cascio and Kellar (1983) have shown saturation of specific tritiated tryptamine binding at 8-10 nM. Owing to the large quantities of radiolabeled tryptamine required in the incubation baths, the concentration required for saturation of specific binding was not determined. Table 2 were added to both incubation baths to determine their effects on specific H3-tryptamine binding. The changes in the specific binding due to the compounds' competition were analyzed by Logit Transformation (Rodbard and Frazier, 1975) to determine the concentration of compound required to inhibit 50% of the specific H3-tryptamine binding (ZC,,). As the Hill coefficient was found to be close to 1 for each of the competing drugs, the ZC,, of each was then converted to an inhibitory constant, K,, where K, = ZC,,l[ 1 + (H3-tryptamine)/K,]. The use of K, allows comparison of the abilities of these compounds to inhibit tryptamine binding with previous studies.
Competition studies Various concentrations of the compounds listed in
Tryptamine hydrochloride had a K, of 4.19 f 2.13 nM, in agreement with the KD of 4.79 nM for H3-tryptamine, indicating a similar affinity of these ligands for the binding sites (Table 2) . Tryptophan, the precursor to tryptamine, and indoleacetic acid, an endogenously formed metabolite of tryptamine, both lacked the ability to inhibit specific H3-tryptamine binding at all concentrations tested. On the other hand, other metabolic products Table 3 for the rat and Table 4 for the dog. Each specific photometer reading indicates the decrease in percentage of transmittance and thereby represents the relative density of specific H3-tryptamine binding. Nonspecific binding was found to be relatively homogeneous throughout the brain and spinal cord. Each value represents the mean of three animals and was calculated by subtracting the nonspecific binding and background film density from the total binding.
Telencephalon (Figs. 4 and 5, Table 3 ) Tryptamine binding sites were densest in the limbic structures.
The highest values were found in the frontal cortex, entorhinal cortex, nucleus accumbens, lateral septal area, anterior olfactory Table 3 ) Within the hypothalamus, the highest binding occurred in the arcuate nucleus, the dorsomedial nucleus, and the periventricular nucleus. Moderate binding was observed in the medial and lateral preoptic areas and in the ventromedial nucleus. Tryptamine binding in the thalamus was highest in the reuniens nucleus, the paraventricular nucleus, and the central medial nucleus. In contrast, the ventrolateral and ventromedial thalamic nuclei, as well as the reticular nucleus, showed low levels of binding. Within the epithalamus, both the medial and lateral habenular nuclei exhibited high binding densities.
Mesencephalon (Figs. 4 and 5, Table 3)
The highest binding occurred in the zonal layer of the superior colliculus, the interpeduncular nucleus and the periaqueductal gray. Binding was substantially lower in the red nucleus and reticular formation.
Myelencephalon and spinal cord (Fig. 6 , Tables 3 and 4) Within the pons and medulla of the rat brain stem, the highest binding occurred in the pontine nuclei, the pontine reticular nucleus (pars oralis), the locus coeruleus and the dorsal tegmental nucleus. In the medulla of the dog, binding was generally high in areas similar to those in the rat. The highest binding in the medulla of the dog was present in the external cuneate nucleus, spinal trigeminal nucleus, gracile nucleus, hypoglossal nucleus, solitary nucleus, and parvocellular reticular nucleus. Binding was low in the gigantocellular reticular nucleus and the inferior olivary nucleus. White-matter tracts exhibited binding similar to or slightly greater than that of the background. Within the spinal cord, tryptamine binding sites were present throughout the gray matter, being highest in the areas of the dorsal and intermediate horns (Fig. 6 and Table 4 ). When analyzed by rostral-caudal segments, binding was highest in the lumbosacral segments of the cord and lowest in the lower cervical region.
Discussion
The present investigation, using in vitro autoradiographic techniques, confirms the studies using tissue homogenates Kellar, 1982, 1983) , indicating that the brain contains specific high-affinity binding sites for H%ryptamine. This method was developed by Young and Kuhar (1979) and has been successfully used to study gamma-aminobutyric acid, serotonin, adrenergic, muscarinic, and opioid binding sites. The results of our kinetic studies showing rapid association and dissociation, the high-specific affinity for labeled and unlabeled tryptamine, and the autoradiographic distribution strongly suggest that the binding observed is a recognition site for tryptamine. The KD obtained in the present study is remarkably similar to that obtained by Cascio and Kellar (1983) .
Our competition studies distinguish this binding site from other binding sites of known and putative neurotransmitters such as serotonin, dopamine, gamma-aminobutyric acid, and phenylethylamine. The precursors D-and L-tryptophan, and the metabolite, indoleacetic acid, failed to inhibit tryptamine binding. However kynuramine, also an endogenous tryptamine metabolite, was found to be a potent inhibitor of tryptamine binding, as previously shown by Charlton et al. (1984) using tissue homogenate preparations. Similarly, another endogenous metabolite of tryptamine, tetrahydrobetacarboline, was found to be a fairly potent displacer of tryptamine binding, as was reported previously by several other investigators using homogenate preparations Rommelspacher and Kaufmann, 1983; Wood et al., 1984) .
Serotonin, whose three-dimensional structure is similar to tryptamine, was found to be only a weak inhibitor of H3-tryptamine binding, suggesting a class of binding sites distinct from those of serotonin. LSD, a commonly used ligand in serotonin binding studies, failed to inhibit tryptamine binding. Fluoxetine, a serotonin reuptake inhibitor, was as ineffective as serotonin in inhibiting tryptamine binding; it would thus appear that the tryptamine binding site is distinct from both the LSD and serotonin binding site and the serotonin reuptake site.
Phenylethylamine (PEA) has been previously reported to displace H3-tryptamine in tissue homogenate studies (Cascio and Kellar, 1983) . Our results confirm the ability of PEA to displace HUyptamine binding. A recent abstract presented by Martin et al. (1984) comparing various PEA derivatives indicates that The above density values were obtained from three dogs.
2.9 f 3.5 8.9 k 6.1 9.5 + 8.5 14.5 t-3. A computerized image analysis system was used, as described previously (Beitz and Buggy, 198 1) .
para-methoxyphenylpropylamine is the most potent displacer of H%yptamine. By comparing the abilities of these PEA derivatives, they concluded that the tryptamine binding site is composed of a large flat lipophilic site that lies distal to an anionic site. The in vitro autoradiographic localization of HQyptamine binding sites in the rat brain was first reported by Perry et al. (1982) ; they reported binding to be highest in the areas of the striatum, hippocampus, and cortex. Our results also indicate that binding is highest in the limbic structures and cortex, cor- Figure 6 . Representative autoradiographic image of HU-yptamine binding in the ventral ( VH) and dorsal (OH) horns of the thoracic region of the canine spinal cord. This image illustrates the high binding in gray matter relative to the surrounding white matter. In general, binding to white-matter structures was no greater than to background. relating well with this initial autoradiographic study as well as with studies in which the binding was examined in homogenates of various brain regions (Cascio and Kellar, 1983; Wood et al., 1984) . In general, tryptamine binding appears to be highest in more rostra1 structures and decreases progressively toward the more caudal brain areas. While the H3-tryptamine binding sites are distinct from those of serotonin, there appears to be some overlap in the distribution of the binding sites of these two indoleamines-for example, in cortical and hippocampal regions (Bigeon et al., 1982; Nakada et al., 1984; Palacios et al., 1983) . However, serotonin, binding sites are highest in the subiculum and dentate gyrus while serotonin, binding sites are found in highest concentrations in the cerebral cortex, caudateputamen, nucleus accumbens, mammillary nucleus, and the inferior olive. In the present study, tryptamine binding sites are most dense in the nucleus accumbens, the amygdalohippocampal area, and the cerebral cortex, where they appear to overlap with the distribution of serotonin, binding sites. However, tryptamine binding sites are low in mammillary nuclei and nondetectable in the inferior olivary nucleus, indicating differences between serotonin, and tryptamine binding sites.
The use of the dog for the autoradiographic localization of H3-tryptamine binding allows even greater delineation of areas containing tryptamine binding sites because of the large size of the canine spinal cord and brain stem. Tryptamine binding was found to be relatively low in canine spinal structures. A comparison of binding densities between the rat and the dog indicates that tryptamine binding sites are distributed in similar areas of the medulla in these two species.
The anatomical distribution of tryptamine binding sites in the CNS and the high degree of pharmacologic specificity of agents in their ability to inhibit this binding suggest that the H3-tryptamine binding site may be a receptor for tryptamine. The physiologic significance of the ability of kynuramine, tetrahydrobetacarboline and PEA to inhibit H3-tryptamine binding remains obscure.
As tryptamine has a high affinity for H3-tryptamine binding sites, a differential distribution of endogenously formed tryptamine could potentially result in a local inhibition of labeled tryptamine binding, thus falsifying the distribution of regional binding sites. However, one would expect this effect to be min-imal in the brain and spinal cord, as mass spectrum analysis indicates that tryptamine is found in very low concentrations in this tissue (Philips et al., 1974) relative to the concentration necessary to displace a significant amount of labeled tryptamine. In addition, much of the endogenously formed tryptamine would be metabolized or diffuse from the tissue during the 5 min preincubation period. Since tryptamine undergoes an exceptionally rapid metabolism compared either to serotonin or norepinephrine, it is unlikely that endogenous tryptamine is present in sufficient amounts to affect the binding of tritiated tryptamine in the present study.
The concentration of endogenous tryptamine has been generally found to be highest in the caudate, hippocampus, and hypothalamus and lowest in the brain stem and cerebellum (Jones, 1982; Philips et al., 1974) . This distribution of indoleamine correlates well with the distribution of binding reported in the present study, showing high binding in the limbic system and striatum and the lowest binding in the cerebellum and lower brain stem. It has been previously proposed that tryptamine acts in the CNS to modulate the activity of serotonin (Jones and Boulton, 1980) . Other studies have shown that tryptamine produces effects that are opposite to those produced by serotonin on the C-fiber reflex, mono-and polysynaptic reflexes (Bell and Martin, 1974) , and nociceptive activity after its intrathecal injection in conscious rats (Larson, 1983) . This is consistent with our finding of H3-tryptamine binding sites in the dorsal and ventral horns of the spinal cord. The present study shows the highest density of H3-tryptamine binding sites in the nucleus accumbens. A recent report indicates that injection of tryptamine into this region evokes intense locomotor activity (Altar et al., 1985) . In,addition to its effects on locomotion, tryptamine has also been implicated in various psychiatric disorders and physiological functions, as reviewed by Jones (1982) .
